International Journal of Endocrinology and Metabolism

Published by: Kowsar

Outcomes of a Longitudinal Population-based Cohort Study and Pragmatic Community Trial: Findings from 20 Years of the Tehran Lipid and Glucose Study

Davood Khalili 1 , 2 , Fereidoun Azizi 3 , * , Samaneh Asgari 1 , Azita Zadeh-Vakili 4 , Amir Abbas Momenan 1 , Arash Ghanbarian 1 , Fatemeh Eskandari 1 , Farhad Sheikholeslami 1 and Farzad Hadaegh 1
Authors Information
1 Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Endocrinology and Metabolism: October 2018, 16 (4 (Suppl)); e84748
  • Published Online: October 13, 2018
  • Article Type: Review Article
  • Received: September 1, 2018
  • Revised: October 2, 2018
  • Accepted: October 7, 2018
  • DOI: 10.5812/ijem.84748

To Cite: Khalili D, Azizi F, Asgari S, Zadeh-Vakili A , Momenan A A, et al. Outcomes of a Longitudinal Population-based Cohort Study and Pragmatic Community Trial: Findings from 20 Years of the Tehran Lipid and Glucose Study, Int J Endocrinol Metab. 2018 ; 16(4 (Suppl)):e84748. doi: 10.5812/ijem.84748.

Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13(9 Suppl):S122-8. [PubMed: 14575944].
  • 2. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, et al. Surveillance and ascertainment of cardiovascular events. The cardiovascular health study. Ann Epidemiol. 1995;5(4):278-85. [PubMed: 8520709].
  • 3. Tager IB. Outcomes in cohort studies. Epidemiol Rev. 1998;20(1):15-28. [PubMed: 9762506].
  • 4. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed. 2002;47(6):408-26. [PubMed: 12643001].
  • 5. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran lipid and glucose study phase II. Trials. 2009;10:5. doi: 10.1186/1745-6215-10-5. [PubMed: 19166627]. [PubMed Central: PMC2656492].
  • 6. Dowse GK, Zimmet P. A model protocol for a diabetes and other noncommunicable disease field survey. World Health Stat Q. 1992;45(4):360-72. [PubMed: 1299078].
  • 7. Puska P, Tuomilehto J, Nissinen A, Salonen J. Ten years of the North Karelia project. Acta Med Scand Suppl. 1985;701:66-71. [PubMed: 3865504].
  • 8. [No Authors Listed]. An international controlled trail in the multifactorial prevention of coronary heart disease. Int J Epidemiol. 1974;3(3):219-24. [PubMed: 4606212].
  • 9. Ghasemzadeh Z, Abdi H, Asgari S, Tohidi M, Khalili D, Valizadeh M, et al. Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population. Nutr Metab (Lond). 2016;13:43. doi: 10.1186/s12986-016-0102-1. [PubMed: 27346994]. [PubMed Central: PMC4919865].
  • 10. Eslami A, Mozaffary A, Derakhshan A, Azizi F, Khalili D, Hadaegh F. Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran lipid and glucose study. Int J Cardiol. 2017;227:826-32. doi: 10.1016/j.ijcard.2016.10.037. [PubMed: 27829526].
  • 11. Khalili D, Sheikholeslami FH, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: A 10-year population-based cohort study. PLoS One. 2014;9(8). e105804. doi: 10.1371/journal.pone.0105804. [PubMed: 25162590]. [PubMed Central: PMC4146560].
  • 12. Zafari N, Asgari S, Lotfaliany M, Hadaegh A, Azizi F, Hadaegh F. Impact of hypertension versus diabetes on cardiovascular and all-cause mortality in Iranian older adults: Results of 14 years of follow-up. Sci Rep. 2017;7(1):14220. doi: 10.1038/s41598-017-14631-2. [PubMed: 29079827]. [PubMed Central: PMC5660198].
  • 13. Derakhshan A, Sardarinia M, Khalili D, Momenan AA, Azizi F, Hadaegh F. Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran lipid and glucose study. PLoS One. 2014;9(7). e102563. doi: 10.1371/journal.pone.0102563. [PubMed: 25029368]. [PubMed Central: PMC4100911].
  • 14. Hadaegh F, Derakhshan A, Zafari N, Khalili D, Mirbolouk M, Saadat N, et al. Pre-diabetes tsunami: Incidence rates and risk factors of pre-diabetes and its different phenotypes over 9 years of follow-up. Diabet Med. 2017;34(1):69-78. doi: 10.1111/dme.13034. [PubMed: 26606421].
  • 15. Bozorgmanesh M, Hadaegh F, Mehrabi Y, Azizi F. A point-score system superior to blood pressure measures alone for predicting incident hypertension: Tehran lipid and glucose study. J Hypertens. 2011;29(8):1486-93. doi: 10.1097/HJH.0b013e328348fdb2. [PubMed: 21720268].
  • 16. Hadaegh F, Hasheminia M, Abdi H, Khalili D, Bozorgmanesh M, Arshi B, et al. Prehypertension tsunami: A decade follow-up of an Iranian adult population. PLoS One. 2015;10(10). e0139412. doi: 10.1371/journal.pone.0139412. [PubMed: 26439847]. [PubMed Central: PMC4595371].
  • 17. Asgari S, Khalili D, Mehrabi Y, Kazempour-Ardebili S, Azizi F, Hadaegh F. Incidence and risk factors of isolated systolic and diastolic hypertension: A 10 year follow-up of the Tehran lipids and glucose study. Blood Press. 2016;25(3):177-83. doi: 10.3109/08037051.2015.1116221. [PubMed: 26643588].
  • 18. Hadaegh F, Hasheminia M, Lotfaliany M, Mohebi R, Azizi F, Tohidi M. Incidence of metabolic syndrome over 9 years follow-up; the importance of sex differences in the role of insulin resistance and other risk factors. PLoS One. 2013;8(9). e76304. doi: 10.1371/journal.pone.0076304. [PubMed: 24086723]. [PubMed Central: PMC3785433].
  • 19. Tohidi M, Hasheminia M, Mohebi R, Khalili D, Hosseinpanah F, Yazdani B, et al. Incidence of chronic kidney disease and its risk factors, results of over 10 year follow up in an Iranian cohort. PLoS One. 2012;7(9). e45304. doi: 10.1371/journal.pone.0045304. [PubMed: 23028919]. [PubMed Central: PMC3459968].
  • 20. Amouzegar A, Ghaemmaghami Z, Beigy M, Gharibzadeh S, Mehran L, Tohidi M, et al. Natural course of euthyroidism and clues for early diagnosis of thyroid dysfunction: Tehran thyroid study. Thyroid. 2017;27(5):616-25. doi: 10.1089/thy.2016.0409. [PubMed: 28071990].
  • 21. Bozorgmanesh M, Hadaegh F, Ghaffari S, Harati H, Azizi F. A simple risk score effectively predicted type 2 diabetes in Iranian adult population: Population-based cohort study. Eur J Public Health. 2011;21(5):554-9. doi: 10.1093/eurpub/ckq074. [PubMed: 20534689].
  • 22. Bozorgmanesh M, Hadaegh F, Azizi F. Beta-cell age calculator, a translational yardstick to communicate diabetes risk with patients: Tehran lipid and glucose study. ISRN Family Med. 2013;2013:541091. doi: 10.5402/2013/541091. [PubMed: 24967319]. [PubMed Central: PMC4041251].
  • 23. Khalili D, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: The Tehran lipid and glucose study. Am J Epidemiol. 2012;176(3):177-86. doi: 10.1093/aje/kws204. [PubMed: 22814370].
  • 24. Khalili D, Asgari S, Hadaegh F, Steyerberg EW, Rahimi K, Fahimfar N, et al. A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study. Int J Cardiol. 2015;184:587-94. doi: 10.1016/j.ijcard.2015.03.067. [PubMed: 25769004].
  • 25. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): A pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015;3(5):339-55. doi: 10.1016/S2213-8587(15)00081-9. [PubMed: 25819778].
  • 26. Ueda P, Woodward M, Lu Y, Hajifathalian K, Al-Wotayan R, Aguilar-Salinas CA, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: A pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol. 2017;5(3):196-213. doi: 10.1016/S2213-8587(17)30015-3. [PubMed: 28126460]. [PubMed Central: PMC5354360].
  • 27. Fahimfar N, Khalili D, Sepanlou SG, Malekzadeh R, Azizi F, Mansournia MA, et al. Cardiovascular mortality in a Western Asian country: Results from the Iran cohort consortium. BMJ Open. 2018;8(7). e020303. doi: 10.1136/bmjopen-2017-020303. [PubMed: 29980541]. [PubMed Central: PMC6042599].
  • 28. Amouzegar A, Gharibzadeh S, Kazemian E, Mehran L, Tohidi M, Azizi F. The prevalence, incidence and natural course of positive antithyroperoxidase antibodies in a population-based study: Tehran thyroid study. PLoS One. 2017;12(1). e0169283. doi: 10.1371/journal.pone.0169283. [PubMed: 28052092]. [PubMed Central: PMC5215694].
  • 29. Parizadeh D, Ghahvehchian H, Asgari S, Momenan AA, Azizi F, Hadaegh F. The association between changes in blood pressure components and incident cardiovascular diseases. Blood Press. 2017;26(6):341-9. doi: 10.1080/08037051.2017.1353882. [PubMed: 28708028].
  • 30. Mozaffary A, Asgari S, Tohidi M, Kazempour-Ardebili S, Azizi F, Hadaegh F. Change in fasting plasma glucose and incident type 2 diabetes mellitus: Results from a prospective cohort study. BMJ Open. 2016;6(5). e010889. doi: 10.1136/bmjopen-2015-010889. [PubMed: 27217283]. [PubMed Central: PMC4885425].
  • 31. Mousavi SV, Mohebi R, Mozaffary A, Sheikholeslami F, Azizi F, Hadaegh F. Changes in body mass index, waist and hip circumferences, waist to hip ratio and risk of all-cause mortality in men. Eur J Clin Nutr. 2015;69(8):927-32. doi: 10.1038/ejcn.2014.235. [PubMed: 25369826].
  • 32. Nejat A, Mirbolouk M, Mohebi R, Hasheminia M, Tohidi M, Saadat N, et al. Changes in lipid measures and incident coronary heart disease: Tehran lipid and glucose study. Clin Biochem. 2014;47(13-14):1239-44. doi: 10.1016/j.clinbiochem.2014.03.004. [PubMed: 24657509].
  • 33. Eslami A, Lotfaliany M, Akbarpour S, Azizi F, Hadaegh F. Trend of cardiovascular risk factors in the older Iranian population: 2002-2014. Geriatr Gerontol Int. 2018;18(1):130-7. doi: 10.1111/ggi.13154. [PubMed: 28857406].
  • 34. Jahangiri-Noudeh Y, Akbarpour S, Lotfaliany M, Zafari N, Khalili D, Tohidi M, et al. Trends in cardiovascular disease risk factors in people with and without diabetes mellitus: A Middle Eastern cohort study. PLoS One. 2014;9(12). e112639. doi: 10.1371/journal.pone.0112639. [PubMed: 25461381]. [PubMed Central: PMC4251920].
  • 35. Kalantari S, Khalili D, Asgari S, Fahimfar N, Hadaegh F, Tohidi M, et al. Predictors of early adulthood hypertension during adolescence: A population-based cohort study. BMC Public Health. 2017;17(1):915. doi: 10.1186/s12889-017-4922-3. [PubMed: 29183297]. [PubMed Central: PMC5706303].
  • 36. Hosseinpanah F, Asghari G, Barzin M, Ghareh S, Azizi F. Adolescence metabolic syndrome or adiposity and early adult metabolic syndrome. J Pediatr. 2013;163(6):1663-1669 e1. doi: 10.1016/j.jpeds.2013.07.032. [PubMed: 24011762].
  • 37. Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prev Med. 2010;38(6):628-636 e1. doi: 10.1016/j.amepre.2010.03.003. [PubMed: 20494239].
  • 38. Azizi F, Mirmiran P, Momenan AA, Hadaegh F, Habibi Moeini A, Hosseini F, et al. The effect of community-based education for lifestyle intervention on the prevalence of metabolic syndrome and its components: Tehran lipid and glucose study. Int J Endocrinol Metab. 2013;11(3):145-53. doi: 10.5812/ijem.5443. [PubMed: 24348586]. [PubMed Central: PMC3860109].
  • 39. Tohidi M, Derakhshan A, Akbarpour S, Amouzegar A, Mehran L, Baghbani-Oskouei A, et al. Thyroid dysfunction states and incident cardiovascular events: The Tehran thyroid study. Horm Metab Res. 2018;50(1):37-43. doi: 10.1055/s-0043-121031. [PubMed: 29132170].
  • 40. Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, Khalili D, Hedayati M, et al. Rationale and design of a genetic study on cardiometabolic risk factors: Protocol for the Tehran cardiometabolic genetic study (TCGS). JMIR Res Protoc. 2017;6(2). e28. doi: 10.2196/resprot.6050. [PubMed: 28232301]. [PubMed Central: PMC5344981].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments